Compare MFIC & INMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFIC | INMD |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 842.0M |
| IPO Year | N/A | 2018 |
| Metric | MFIC | INMD |
|---|---|---|
| Price | $11.73 | $13.97 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 7 | 5 |
| Target Price | $11.25 | ★ $17.33 |
| AVG Volume (30 Days) | ★ 736.4K | 653.9K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 10.84% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.74 |
| Revenue Next Year | N/A | $3.26 |
| P/E Ratio | $10.50 | ★ $10.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.48 | $12.72 |
| 52 Week High | $13.51 | $16.74 |
| Indicator | MFIC | INMD |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 47.19 |
| Support Level | $11.34 | $13.32 |
| Resistance Level | $11.81 | $14.70 |
| Average True Range (ATR) | 0.30 | 0.30 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 46.67 | 47.95 |
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.